Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02473354 · ClinicalTrials.gov registry record · Phase 1
Predictors of Opioid-Induced Respiratory Depression (OIRD)
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02473354 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 30 participants.
The verdict
NCT02473354, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Purpose of the Study: (1) To classify an individual subject's ventilatory response in terms of respiratory depression to a bolus of remifentanil under normoxic and hyperoxic conditions. (2) Measurement of specific respiratory parameters to predict the opioid-induced respiratory depression (OIRD) response.
Interventions
- DRUG Oxygen
- DRUG Remifentanil
- DRUG Carbon dioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02473354
The ClinicalTrials.gov registry entry for NCT02473354 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oxygen is the first listed.
NCT02473354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02473354 about?
NCT02473354 is a clinical study titled "Predictors of Opioid-Induced Respiratory Depression (OIRD)". Purpose of the Study: (1) To classify an individual subject's ventilatory response in terms of respiratory depression to a bolus of remifentanil under normoxic and hyperoxic conditions. (2) Measurement of specific respiratory parameters to predict the opioid-induced respiratory depression (OIRD) res...
What is the current status of trial NCT02473354?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-04. Estimated completion is 2018-04-29.
What interventions are being tested in trial NCT02473354?
The interventions under investigation include: Oxygen (DRUG), Remifentanil (DRUG), Carbon dioxide (DRUG).
Who is sponsoring clinical trial NCT02473354?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.